Dilated cardiomyopathy (DCM) is the most common childhood cardiomyopathy and is associated with significant early morbidity and mortality. About half of patients die or require heart transplantation within 5 years of diagnosis. The medical therapy for DCM with heart failure includes anti-congestive medications and antiplatelet therapy. Those who fail to improve within the first year of diagnosis usually deteriorated even upon aggressive anti-congestive medications. The investigators had conducted precision-medicine-based approach to provide strategic approach as drug repurposing to identify new treatments. The investigators have identified the beneficial effects from a statin, simvastatin, to restore the cardiac contractility. The investigators would further assess the efficacy of simvastatin to improve the cardiac function in patients with DCM.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 1st month(The 1st month follow-up time tolerates a 0.5-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 3rd month(The 3rd month follow-up time tolerates a 1-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 6th month(The 6th month follow-up time tolerates a 1-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 9th month(The 9th month follow-up time tolerates a 1-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 12th month(The 12th month follow-up time tolerates a 1-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 15th month(The 15th month follow-up time tolerates a 1-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 18th month(The 18th month follow-up time tolerates a 1-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 21st month(The 21th month follow-up time tolerates a 1-month window )
Change from base line in left ventricular ejection fraction and end-diastolic dimention by cardiac ultrasound.
Timeframe: baseline, 24th month(The 24th month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 3rd month(The 3rd month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 6th month(The 6th month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 9th month(The 9th month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 12th month(The 12th month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 15th month(The 15th month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 18th month(The 18th month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 21st month(The 21th month follow-up time tolerates a 1-month window )
Change from baseline in N-terminal pro-brain natriuretic peptide level.natriuretic peptide level.
Timeframe: baseline, 24th month(The 24th month follow-up time tolerates a 1-month window )